Published in Semin Cancer Biol on April 01, 1990
Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones. J Clin Invest (1994) 1.83
Crystal structures of native and inhibited forms of human cathepsin D: implications for lysosomal targeting and drug design. Proc Natl Acad Sci U S A (1993) 1.67
Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J (1994) 1.61
The breast cancer-associated stromelysin-3 gene is expressed during mouse mammary gland apoptosis. J Cell Biol (1992) 1.55
Gelatinase (MMP-2 and -9) expression in gastrointestinal malignancy. Br J Cancer (1998) 1.53
Expression of interleukin-8 correlates with angiogenesis, tumorigenicity, and metastasis of human prostate cancer cells implanted orthotopically in nude mice. Neoplasia (2001) 1.52
Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A (1994) 1.50
Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer (2003) 1.45
Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. Am J Pathol (1994) 1.38
Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol (1994) 1.36
Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer. PLoS One (2010) 1.31
Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis (2000) 1.19
Transforming growth factor beta mediates the progesterone suppression of an epithelial metalloproteinase by adjacent stroma in the human endometrium. Proc Natl Acad Sci U S A (1995) 1.13
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med (2010) 1.12
6-Shogaol, an active constituent of ginger, inhibits breast cancer cell invasion by reducing matrix metalloproteinase-9 expression via blockade of nuclear factor-κB activation. Br J Pharmacol (2010) 1.11
Localization of mRNAs representing collagenase and TIMP in sections of healing human burn wounds. Am J Pathol (1993) 1.08
Stromal-epithelial interaction mediates steroidal regulation of metalloproteinase expression in human endometrium. Proc Natl Acad Sci U S A (1994) 1.03
Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinomas of the lung using in situ hybridization. Am J Pathol (1994) 1.01
microRNA-125b inhibits cell migration and invasion by targeting matrix metallopeptidase 13 in bladder cancer. Oncol Lett (2013) 1.01
Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics (2012) 1.00
Matrix metalloproteinase inhibitors: present achievements and future prospects. Invest New Drugs (1997) 0.99
Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. Br J Cancer (2003) 0.98
Suppression of local invasion of ameloblastoma by inhibition of matrix metalloproteinase-2 in vitro. BMC Cancer (2008) 0.97
Expression of tissue inhibitor of metalloproteinases TIMP-2 in human colorectal cancer--a predictor of tumour stage. Br J Cancer (1997) 0.96
Establishment of an in vitro assay to measure the invasion of ovarian carcinoma cells through mesothelial cell monolayers. Clin Exp Metastasis (2003) 0.94
Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct (2010) 0.93
Programmed cell death (apoptosis) in cord blood lymphocytes. J Clin Immunol (1997) 0.92
Structure of the human TIMP-3 gene and its cell cycle-regulated promoter. Biochem J (1995) 0.92
Antiproliferative factor decreases Akt phosphorylation and alters gene expression via CKAP4 in T24 bladder carcinoma cells. J Exp Clin Cancer Res (2010) 0.91
Deficiency of chemokine receptor CCR1 causes osteopenia due to impaired functions of osteoclasts and osteoblasts. J Biol Chem (2010) 0.91
Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol (1998) 0.90
Surrogate markers in antiangiogenesis clinical trials. Br J Cancer (2003) 0.90
Markers of bile duct tumors. World J Gastrointest Oncol (2011) 0.90
Expression of the Ets-1 proto-oncogene in human gastric carcinoma: correlation with tumor invasion. Am J Pathol (1996) 0.89
A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs (2007) 0.88
Human leucine zipper protein sLZIP induces migration and invasion of cervical cancer cells via expression of matrix metalloproteinase-9. J Biol Chem (2011) 0.88
The autolytic regulation of human kallikrein-related peptidase 6. Biochemistry (2007) 0.88
Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol (2011) 0.88
Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol (1998) 0.86
Anti-metastatic efficacy and safety of MMI-166, a selective matrix metalloproteinase inhibitor. Clin Exp Metastasis (2000) 0.86
Differential expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in thioacetamide-induced chronic liver injury. J Korean Med Sci (2010) 0.85
The significance of MMP-1 and MMP-2 in peritoneal disseminated metastasis of gastric cancer. Surg Today (2000) 0.84
Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis (1997) 0.84
Infiltrative capacity of T leukemia cell lines: a distinct functional property coupled to expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1). Clin Exp Metastasis (1999) 0.83
Impact of flavonoids on matrix metalloproteinase secretion and invadopodia formation in highly invasive A431-III cancer cells. PLoS One (2013) 0.81
Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin Exp Metastasis (1998) 0.81
A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma. HPB (Oxford) (2005) 0.81
SufA - a bacterial enzyme that cleaves fibrinogen and blocks fibrin network formation. Microbiology (2009) 0.80
Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma. PLoS One (2014) 0.80
Inhibition of proliferation, migration, and matrix metalloprotease production in malignant mesothelioma cells by tyrosine kinase inhibitors. Neoplasia (2005) 0.78
Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation. BMC Clin Pathol (2012) 0.77
Paris saponin VII suppresses osteosarcoma cell migration and invasion by inhibiting MMP‑2/9 production via the p38 MAPK signaling pathway. Mol Med Rep (2016) 0.77
Significance and prognostic value of lysosomal enzyme activities measured in surgically operated adenocarcinomas of the gastroesophageal junction and squamous cell carcinomas of the lower third of esophagus. World J Gastroenterol (2005) 0.75
The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. Br J Cancer (2000) 0.75
Expressions of matrix metalloproteinase-7 and -9 and their prognostic significances in rectal cancer. Cancer Res Treat (2005) 0.75
The molecular biology of colorectal cancer development and the associated genetic events. Ann R Coll Surg Engl (1999) 0.75
Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma. Oncol Lett (2011) 0.75
The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. Clin Exp Metastasis (1998) 0.75
Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73
Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell (1996) 6.52
Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science (1997) 4.83
Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res (1991) 3.47
Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem (1994) 3.37
Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol (1999) 2.91
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res (1990) 2.40
Molecular aspects of tumor cell invasion and metastasis. Cancer (1993) 2.24
Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci U S A (1992) 2.18
Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am J Pathol (1992) 2.17
Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst (1991) 2.15
Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol (1993) 2.01
Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res (2001) 1.99
In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest (1998) 1.95
Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol (1993) 1.88
Immunohistochemical distribution of type IV collagenase in normal, benign, and malignant breast tissue. Am J Pathol (1990) 1.82
Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem (1999) 1.78
Validation of a model of colon cancer progression. J Pathol (2000) 1.76
The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Respir J (1994) 1.68
Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol (1993) 1.65
Matrix metalloproteinases in renal development and disease. J Am Soc Nephrol (2000) 1.64
Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry (1994) 1.63
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer (1998) 1.58
Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol (1997) 1.53
Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res (1991) 1.52
Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem (1992) 1.46
Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J Neurosci (1998) 1.41
Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. Cancer Res (1993) 1.41
Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem (1992) 1.40
Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am J Pathol (1996) 1.40
Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan's syndrome. Circulation (1998) 1.40
Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res (1995) 1.40
Tissue inhibitor of metalloproteinases-2 (TIMP-2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem (2000) 1.39
Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol (1991) 1.39
Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol (1996) 1.38
Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. Am J Pathol (1994) 1.36
Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase. J Biol Chem (1996) 1.36
Expression of 92-kD type IV collagenase/gelatinase (gelatinase B) in osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin 1. J Clin Invest (1993) 1.36
Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J (1995) 1.34
92-kd type IV collagenase (matrix metalloproteinase-9) activity in human amniochorion increases with labor. Am J Pathol (1995) 1.26
Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. Anal Biochem (1997) 1.26
Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metastasis (1998) 1.22
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res (1992) 1.21
Interleukin 10 suppression of monocyte prostaglandin H synthase-2. Mechanism of inhibition of prostaglandin-dependent matrix metalloproteinase production. J Biol Chem (1994) 1.19
MMP-2: expression, activation and inhibition. Enzyme Protein (1996) 1.19
Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol (1994) 1.19
Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst (2001) 1.18
Tumor cell surface-associated binding site for the M(r) 72,000 type IV collagenase. Cancer Res (1992) 1.18
Primate smooth muscle cell migration from aortic explants is mediated by endogenous platelet-derived growth factor and basic fibroblast growth factor acting through matrix metalloproteinases 2 and 9. Circulation (1997) 1.17
Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res (1993) 1.16
Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem (1995) 1.16
Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer (1994) 1.14
Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol (2001) 1.14
Bovine dentin phosphophoryn: composition and molecular weight. Biochemistry (1983) 1.13
Matrix metalloproteinases. Novel targets for directed cancer therapy. Drugs Aging (1997) 1.13
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood (1997) 1.12
Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res (1992) 1.11
Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis (1996) 1.09
Evaluation of hepatocellular carcinoma aggressiveness by a panel of extracellular matrix antigens. Am J Pathol (1991) 1.09
Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis (1996) 1.08
Type I collagen shows a specific binding affinity for bovine dentin phosphophoryn. Calcif Tissue Int (1986) 1.06
Bovine dentin phosphophoryn: calcium ion binding properties of a high molecular weight preparation. Calcif Tissue Int (1987) 1.06
Cancer invasion and metastasis: positive and negative regulatory elements. Cancer Invest (1991) 1.06
The 72 kDa type IV collagenase is modulated via differential expression of alpha v beta 3 and alpha 5 beta 1 integrins during human melanoma cell invasion. Cancer Res (1993) 1.06
Cancer invasion and metastases. JAMA (1990) 1.05
Expression of tissue inhibitors of metalloproteinases: negative regulators of human glioblastoma invasion in vivo. Clin Exp Metastasis (1995) 1.05
Calcium influx modulates expression of matrix metalloproteinase-2 (72-kDa type IV collagenase, gelatinase A). J Biol Chem (1994) 1.05
Injury-induced 92-kilodalton gelatinase and urokinase expression in rat brain. Lab Invest (1994) 1.03
Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex. Kidney Int (1993) 1.02
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem J (1993) 1.01
Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am J Pathol (1999) 1.01
Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol (1992) 1.01
Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloproteinase enzyme prosegment. Cancer Res (1992) 1.00
Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells. J Cell Sci (1996) 0.99
Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood (2001) 0.99
Tumor cell motility. Semin Cancer Biol (1991) 0.99
TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118. Oncogene (2006) 0.98
Autolytic activation of recombinant human 72 kilodalton type IV collagenase. Biochemistry (1995) 0.98
HIV-1 infection alters monocyte interactions with human microvascular endothelial cells. J Immunol (1995) 0.98
The role of metalloproteinases and their inhibitors in hematological disorders. Crit Rev Oncog (1996) 0.98
Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry (1992) 0.97
Growth factors specifically alter hair follicle cell proliferation and collagenolytic activity alone or in combination. Differentiation (1990) 0.96
Follicle-stimulating hormone increases the expression of tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2 and induces TIMP-1 AP-1 site binding complex(es) in prepubertal rat Sertoli cells. Endocrinology (1994) 0.95
Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta. Exp Cell Res (1994) 0.94
TIMP-3 mRNA expression is regionally increased in moderately and poorly differentiated colorectal adenocarcinoma. Br J Cancer (1997) 0.94
Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncol Res (1994) 0.94
Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and motility factor receptor. Cancer Res (1990) 0.94
Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B. Lab Invest (1996) 0.94
Monocyte membrane type 1-matrix metalloproteinase. Prostaglandin-dependent regulation and role in metalloproteinase-2 activation. J Biol Chem (2001) 0.94
Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett (1995) 0.94
Posttranscriptional stimulation of endothelial cell matrix metalloproteinases 2 and 1 by endothelioma cells. Exp Cell Res (2000) 0.93
Urinary type IV collagenase: elevated levels are associated with bladder transitional cell carcinoma. Cancer Epidemiol Biomarkers Prev (1993) 0.92
Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. Biochem Cell Biol (1996) 0.92
Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP-1) in a more tumourigenic colon cancer cell line. J Pathol (2000) 0.92
Stability analysis of latent and active 72-kDa type IV collagenase: the role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry (1993) 0.92
Immunohistochemical study of matrix metalloproteinases and their tissue inhibitors in pulmonary Langerhans' cell granulomatosis. Arch Pathol Lab Med (1997) 0.92
Human glomeruli express TIMP-1 mRNA and TIMP-2 protein and mRNA. Am J Physiol (1993) 0.91